Sidoti Csr Equities Analysts Cut Earnings Estimates for USNA

USANA Health Sciences, Inc. (NYSE:USNA) – Equities researchers at Sidoti Csr dropped their Q4 2027 earnings per share estimates for USANA Health Sciences in a report released on Wednesday, February 11th. Sidoti Csr analyst A. Lebiedzinski now forecasts that the company will post earnings of $0.75 per share for the quarter, down from their previous estimate of $0.76. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share.

Several other equities research analysts also recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, December 29th. Zacks Research downgraded shares of USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 7th. Two research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, USANA Health Sciences has a consensus rating of “Reduce” and a consensus price target of $36.00.

USANA Health Sciences Stock Performance

NYSE:USNA opened at $20.95 on Friday. The stock has a market cap of $382.97 million, a price-to-earnings ratio of 23.81, a PEG ratio of 0.90 and a beta of 0.67. USANA Health Sciences has a 1 year low of $18.48 and a 1 year high of $38.32. The business has a fifty day moving average of $20.68 and a 200-day moving average of $23.84.

Hedge Funds Weigh In On USANA Health Sciences

Hedge funds have recently made changes to their positions in the business. National Bank of Canada FI lifted its stake in USANA Health Sciences by 166.6% during the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after purchasing an additional 1,201 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of USANA Health Sciences by 382.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after acquiring an additional 1,901 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of USANA Health Sciences by 1,354.3% during the 4th quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock worth $76,000 after acquiring an additional 3,589 shares in the last quarter. CWM LLC boosted its stake in shares of USANA Health Sciences by 109.7% during the 2nd quarter. CWM LLC now owns 2,762 shares of the company’s stock worth $84,000 after acquiring an additional 1,445 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of USANA Health Sciences by 52.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock worth $106,000 after acquiring an additional 1,327 shares during the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.